Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

[F-18] RGD-K5 Positron Emission Tomography (PET) in Participants With Carotid Artery Stenosis

Study:

An Exploratory, Phase II, Open Label, Single-Center, Non-Randomized Study Of [F-18] RGD-K5 Positron Emission Tomography (PET) In Participants With Carotid Artery Stenosis

Rationale:

n/a

Purpose:

This trial will be the first trial for the Investigation Product (IP), [F-18]RGD-K5 for carotid plaque imaging and will be conducted as a Phase II trial since this compound has already been tested in humans for phase I and phase II imaging. All study results will be evaluated and analyzed in order to consider the design for future clinical trials.

Study Status: Recruiting

Recruiting:
Claire Parker 216-445-6821 parkerc@ccf.org

Condition Intervention Phase
Carotid Stenosis Drug: [F-18]RDG-K5 Phase 2

Verified by Siemens Molecular Imaging February, 2013

Sponsored by: Siemens Molecular Imaging
Information provided by: Siemens Molecular Imaging
ClinicalTrials.gov identifier: NCT01602471

Study Type: Interventional

Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Cleveland Clinic
Cleveland, Ohio 44195
United States

Balaji Tamarappoo, MD, PhD., Principal Investigator
Edward Aten, MD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.